Medicare Negotiation and Competitive Licensing Act of 2018
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jul 25, 2018)
Medicare Negotiation and Competitive Licensing Act of 2018
This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.)
The CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities.
Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).
What just happenedAug 3, 2018
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseJul 25, 2018
- Aug 3, 2018Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jul 27, 2018Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jul 25, 2018IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Jul 25, 2018IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Jul 25, 2018IntroReferralIntro-H
Introduced in House
- Jul 25, 2018IntroReferral1000
Introduced in House